Advanced search
Publication Cover
Hematology Volume 26, 2021 - Issue 1
Submit an article Journal homepage
3,000
Views
2
CrossRef citations to date
0
Altmetric
Articles

Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in the United Kingdom and Ireland (TRAPeze UK & IE study)

Vickie McDonalda Department of Haematology, The Royal London Hospital, Barts Health NHS Trust, London, UKCorrespondence[email protected]
View further author information
,
Adrian Newlandb Academic Haematology Unit, Blizard Institute, Barts, London, UK;c The London School of Medicine & Dentistry, Queen Mary Institute of London, London, UKView further author information
,
Mervyn Morgand ITP Support Association, Bedfordshire, UKView further author information
,
Koo Wilsone Swedish Orphan Biovitrum AB, Stockholm, SwedenView further author information
,
Jameel Nazire Swedish Orphan Biovitrum AB, Stockholm, SwedenView further author information
,
Peter Maguiref Wickenstones Ltd, Oxfordshire, UKView further author information
,
Emma Geldmanf Wickenstones Ltd, Oxfordshire, UKView further author information
&
Tammy Wynnef Wickenstones Ltd, Oxfordshire, UKView further author information
 show all
Pages 799-808 | Published online: 02 Oct 2021

References

  • Li J, Ma S, Shao L, et al. Inflammation-related gene polymorphisms associated with primary immune thrombocytopenia. Front Immunol. 2017;8:744.
  • Khan AM, Mydra H, Nevarez A. Clinical practice updates in the management of immune thrombocytopenia. Pharm Ther. 2017;42(12):756–763.
  • Kayal L, Jayachandran S, Singh K. Idiopathic thrombocytopenic purpura. Contemp Clin Dent. 2014;5(3):410–414.
  • Neunert C, Terrell DR, Arnold DM, et al. American society of hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–3866.
  • Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780–3817.
  • Matzdorff A, Meyer O, Ostermann H, et al. Immune thrombocytopenia – current diagnostics and therapy: recommendations of a joint working group of DGHO, OGHO, SGH, GPOH, and DGTI. Oncol Res Treat. 2018;41(Suppl. 5):1–30.
  • Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–2393.
  • Arnold DM. Bleeding complications in immune thrombocytopenia. Hematol Am Soc Hematol Educ Program. 2015;2015:237–242.
  • Pavord S, Thachil J, Hunt BJ, et al. Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic. Br J Haematol. 2020;189(6):1038–1043.
  • Schipperus M, Kaiafa G, Taylor L, et al. Assessment of self-administration of romiplostim in patients with immune thrombocytopenic purpura after receipt of home administration training materials: a cross-sectional study. Drug Saf. 2019;42(1):77–83.
  • EMC. Romiplostim SmPC 2020. Available from: https://www.medicines.org.uk/emc/product/567/smpc.
  • EMC. Eltrombopag SmPC 2021. Available from: https://www.medicines.org.uk/emc/product/508/smpc.
  • EMC. Avatrombopag SmPC. 2021.
  • Cooper N. State of the art – how I manage immune thrombocytopenia. Br J Haematol. 2017;177(1):39–54.
  • Al-Samkari H, Kuter DJ. Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. Ther Adv Hematol. 2019;10. doi:https://doi.org/10.1177/2040620719841735.
  • Ghanima W, Cooper N, Rodeghiero F, et al. Thrombopoietin receptor agonists: ten years later. Haematologica. 2019;104(6):1112–1123.
  • Al-Samkari H, Kuter DJ. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia. Am J Hematol. 2018;93(12):1501–1508.
  • Thachil J, Bagot C, Bradbury C, et al. A United Kingdom immune thrombocytopenia (ITP) forum review of practice: thrombopoietin receptor agonists. Br J Haematol. 2018;180(4):591–594.
  • Diraimo J, Kruse C, Lambert MP, et al. Impact of therapy choice on fatigue in adults with immune thrombocytopenia. Blood. 2020;136(Supplement 1):19–20.
  • Cooper N, Kruse A, Kruse C, et al. Immune thrombocytopenia (ITP) World Impact Survey (iWISh): patient and physician perceptions of diagnosis, signs and symptoms, and treatment. Am J Hematol. 2021;96(2):188–198.
  • HPRA. Your practical guide to RevoladeTM (eltrombopag). 2016.
  • Kruse C, Kruse A, Watson S, et al. Patients with immune thrombocytopenia (ITP) frequently experience severe fatigue but is it under-recognized by physicians: results from the ITP World Impact Survey (I-WISh). Blood. 2018;132(Supplement 1):2273.
  • Cooper N, Kruse C, Kruse A, et al. Patient perceptions on splenectomy outcomes: results from the ITP World Impact Survey (I-WISH): PF714. HemaSphere. 2019;3:312.
  • Raheja P, Miah H, Miah A, et al. Therapeutic landscape in primary immune thrombocytopenia over the last three decades in the United Kingdom (UK adult primary ITP registry project) (PB0818). Res Pract Thromb Haemost. 2021;5(Suppl 1).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.